Tearful is a medical diagnostics company focused on transforming Dry Eye Disease (DED) evaluation through i-Onion™ device the worlds first patented device for assessing the maximal secretion capacity of the lacrimal gland. Our technology the i-Onion™ is a portable, easy-to-use diagnostic tool that uses a gentle CO2 puff to stimulate reflex tear production. This allows clinicians to measure true lacrimal gland reserve in a safe, standardized, and objective way.
Unlike existing tools that provide static observations of tear film, i-Onion™ delivers functional insight into the eye’s ability to produce tears, enabling better treatment decisions for DED, digital eye strain, contact lens intolerance, LASIK patients, and even veterinary ophthalmology.
We are CE-mark approved and FDA filing is in progress (less than 3 months ready for approval). Our innovation has been validated through trials at the Instituto de Neurociencias, Universidad Miguel Hernández (Spain), Clínica Oftalmologica Fernández Vega (Spain), the Bascom Palmer Eye Institute (USA) and several key peer-reviewed publications. With 15 working prototypes, 450+ patients tested, and growing interest from major ophthalmology and optometric companies, we are poised for global scale-up. Our leadership team brings a successful exit track record (AR-15512, acquired by Aerie, then Alcon).
Key Outcome Goals:
– Finalize FDA clearance
– Launch US commercialization with CMO production and salesforce
– Build strategic clinical and investor partnerships
– Achieve CMS reimbursement